A trailblazing study conducted by researchers at the Laureate Institute for Brain Research (LIBR) in Tulsa, Okla., has made significant strides with a novel technique for treating anorexia nervosa (AN), an eating disorder characterized by low body weight, body image abnormalities, and anxiety.
Novel Anti-CD40L Antibody Slows New Brain Lesions in Relapsing MS
Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.